NASDAQ:MGX Metagenomi (MGX) Stock Price, News & Analysis $1.78 +0.13 (+7.88%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$1.84 +0.06 (+3.37%) As of 08:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Metagenomi Stock (NASDAQ:MGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Metagenomi alerts:Sign Up Key Stats Today's Range$1.66▼$1.8250-Day Range$1.26▼$1.7852-Week Range$1.23▼$6.90Volume338,477 shsAverage Volume786,649 shsMarket Capitalization$66.54 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingBuy Company OverviewMetagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.Read More… Metagenomi Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreMGX MarketRank™: Metagenomi scored higher than 51% of companies evaluated by MarketBeat, and ranked 600th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMetagenomi has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMetagenomi has only been the subject of 3 research reports in the past 90 days.Read more about Metagenomi's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Metagenomi are expected to decrease in the coming year, from ($2.46) to ($2.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Metagenomi is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Metagenomi is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Metagenomi's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.02% of the float of Metagenomi has been sold short.Short Interest Ratio / Days to CoverMetagenomi has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Metagenomi has recently decreased by 18.92%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMetagenomi does not currently pay a dividend.Dividend GrowthMetagenomi does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.02% of the float of Metagenomi has been sold short.Short Interest Ratio / Days to CoverMetagenomi has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Metagenomi has recently decreased by 18.92%, indicating that investor sentiment is improving significantly. News and Social Media3.4 / 5News Sentiment1.11 News SentimentMetagenomi has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Metagenomi this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for MGX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Metagenomi to their MarketBeat watchlist in the last 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Metagenomi insiders have not sold or bought any company stock.Read more about Metagenomi's insider trading history. Receive MGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Metagenomi and its competitors with MarketBeat's FREE daily newsletter. Email Address MGX Stock News HeadlinesMetagenomi, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMay 16, 2025 | finance.yahoo.com2MGX : Demystifying Metagenomi: Insights From 4 Analyst ReviewsMay 15, 2025 | benzinga.comElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.May 30, 2025 | Colonial Metals (Ad)Metagenomi Reports Promising Hemophilia A Study ResultsMay 15, 2025 | tipranks.comMetagenomi, Inc.: Metagenomi Reports Business Updates and First Quarter 2025 Financial ResultsMay 14, 2025 | finanznachrichten.deMetagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025May 14, 2025 | globenewswire.comMetagenomi Reports Business Updates and First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comMetagenomi to Present at Upcoming Scientific MeetingsMay 2, 2025 | globenewswire.comSee More Headlines MGX Stock Analysis - Frequently Asked Questions How have MGX shares performed this year? Metagenomi's stock was trading at $3.61 at the beginning of 2025. Since then, MGX shares have decreased by 50.7% and is now trading at $1.78. View the best growth stocks for 2025 here. How were Metagenomi's earnings last quarter? Metagenomi, Inc. (NASDAQ:MGX) issued its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by $0.06. The business earned $4.13 million during the quarter, compared to the consensus estimate of $8.75 million. Metagenomi had a negative net margin of 134.27% and a negative trailing twelve-month return on equity of 43.23%. When did Metagenomi IPO? Metagenomi (MGX) raised $94 million in an IPO on Friday, February 9th 2024. The company issued 6,250,000 shares at $15.00 per share. Who are Metagenomi's major shareholders? Metagenomi's top institutional investors include Hhlr Advisors LTD. (0.40%), AQR Capital Management LLC (0.23%), Goldman Sachs Group Inc. (0.21%) and Nuveen LLC (0.17%). Insiders that own company stock include Holdings A/S Novo and Pamela Wapnick. View institutional ownership trends. How do I buy shares of Metagenomi? Shares of MGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Metagenomi own? Based on aggregate information from My MarketBeat watchlists, some other companies that Metagenomi investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings5/13/2025Today5/29/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MGX Previous SymbolNASDAQ:MGX CIK1785279 Webwww.metagenomi.co Phone510-871-4880FaxN/AEmployees236Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$17.00 Low Stock Price Target$7.00 Potential Upside/Downside+630.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$68.25 million Net Margins-134.27% Pretax Margin-137.13% Return on Equity-43.23% Return on Assets-18.86% Debt Debt-to-Equity RatioN/A Current Ratio6.18 Quick Ratio6.18 Sales & Book Value Annual Sales$45.26 million Price / Sales1.47 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares37,381,000Free FloatN/AMarket Cap$66.54 million OptionableN/A Beta-0.65 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:MGX) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon Musk’s Frightening Warning Forces Trump’s HandElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.